GlassScriptPhysician profile
Jay C Chanmugam
NPI 1518905207
$9,121.45
in general payments reported to CMS, 2019-2025
34 companies · $2,656 in 2025
The $2,656 reported for 2025 was more than what 97% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $102 · 2021: $536 · 2022: $1,366 · 2023: $1,897 · 2024: $2,086 · 2025: $2,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,639.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,724.21 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,626.94 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $839.11 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $522.77 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Indivior INC. | $388.20 | 2019-2025 | Sublocade |
| Lilly USA, LLC | $383.86 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $353.83 | 2025 | Caplyta |
| Amgen INC. | $294.68 | 2021-2024 | Repatha, Otezla |
| Eisai INC. | $274.81 | 2025 | |
| Braeburn INC. | $249.35 | 2023-2025 | Brixadi |
| Exact Sciences Corporation | $173.05 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $163.05 | 2022-2023 | Spravato |
| Pfizer INC. | $145.14 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $139.54 | 2024 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $124.97 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $100.00 | 2022 | |
| Orexo US, INC. | $91.22 | 2019-2020 | |
| Boston Scientific Corporation | $85.93 | 2019 | |
| Scilex Pharmaceuticals INC. | $84.59 | 2021-2022 | |
| Insulet Corporation | $69.24 | 2021-2023 | Omnipod |
| Abbott Laboratories | $35.53 | 2021-2023 | Proclaim |
| Aytu Biopharma, INC. | $31.26 | 2020-2024 | Karbinal |
| Astellas Pharma US INC | $28.05 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $25.64 | 2022 | |
| Axsome Therapeutics, INC. | $25.15 | 2025 | Symbravo |
| Merck Sharp & Dohme LLC | $22.96 | 2023 | Verquvo, Steglatro |
| Axonics, INC. | $22.41 | 2023 | Axonics |
| Biohaven Pharmaceutical Holding Company LTD. | $19.08 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.88 | 2025 | Voquezna |
| Photonicare INC | $17.25 | 2023 | Otosight Middle Ear Scope |
| Kowa Pharmaceuticals America, INC. | $14.87 | 2025 | Zoryve |
| Ibsa Pharma INC. | $13.20 | 2023 | Tirosint, Licart |
| Esperion Therapeutics, INC. | $12.68 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Chanmugam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.